基于App的非药物干预改善中轴型脊柱关节炎患者报告结局:一项随机对照试验
这项12周单中心随机对照试验纳入200例中轴型脊柱关节炎(axSpA)患者,评估CE认证的Axia智能手机应用(结合个性化运动、患者教育和疾病管理,并辅以游戏化设计)对比标准治疗的效果。结果显示,Axia组在BASDAI、BASFI和ASQoL上均显著优于对照组,且ASAS20/40应答率更高,无安全性信号。
要点
- Axia作为非药物干预安全有效,可辅助常规抗炎药物治疗。
核心结论
- Axia应用作为非药物干预可安全有效地改善axSpA患者的疾病活动度、功能和生活质量。
研究设计与样本
- 12周单中心随机对照干预试验,纳入200例药物治疗稳定的axSpA患者,按1:1随机分为Axia组和标准治疗组。
主要发现
- 未观察到令人担忧的安全性信号。
关键数值与推荐
- Axia组BASDAI、BASFI和ASQoL的改善均超过最小临床重要差异阈值。
临床怎么用
- 对于药物治疗稳定的axSpA患者,可考虑将Axia应用作为辅助非药物干预,以进一步改善疾病活动度、功能和生活质量。
局限性
- 研究为12周单中心设计,长期疗效和外部推广性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: No app-based nonpharmacological intervention has yet demonstrated to meaningfully improve disease activity, functional status, and disease-specific quality of life in axial spondyloarthritis (axSpA). We evaluated Axia, a CE-marked smartphone application designed for axSpA, that combines personalised exercise therapy, patient education, and disease management, supported by gamification for long-term adherence. METHODS: To evaluate its clinical efficacy, a 12-week monocentric randomised controlled interventional trial was conducted involving 200 patients with axSpA with stable pharmacotherapy. Patients were randomised (1:1) to either using Axia (intervention group [IG]) or standard of care (control group [CG]). RESULTS: A total of 186 participants (mean age 50.61 years, 66% females, 56% with radiographic axSpA, mean Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] 5.17, and 58% received biologicals or Janus kinase inhibitors) completed the study (95 in the IG and 91 in the CG). Compared to CG, participants in the IG demonstrated significant improvements in BASDAI (analysis of covariance [ANCOVA]-estimated group difference: -1.508, P < .001), Bath Ankylosing Spondylitis Functional Index (-1.139; P < .001), and Ankylosing Spondylitis Quality of Life questionnaire (-2.297; P < .001), all exceeding minimal clinically important difference thresholds. A significantly higher proportion of patients in the IG achieved an Assessment of Spondyloarthritis International Society (ASAS)20 response compared to the CG (51% vs 9%; P < .001), and the ASAS40 response rate was also higher (23% vs 3%; P < .001). No concerning safety signals were observed. CONCLUSIONS: These findings support the potential of Axia as a safe and effective nonpharmacological intervention to further improve the state of care of patients with axSpA in addition to conventional anti-inflammatory pharmacotherapy.
引用
- Strunz PP, Froehlich M, Heusinger T, et al. An app-based nonpharmacological intervention improves patient-reported disease activity, functionality, and quality of life in patients with axial spondyloarthritis: a randomised controlled trial. Ann Rheum Dis. 2026. PMID: 41826215. doi:10.1016/j.ard.2026.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。